N-(4-羟基苯基)-2-甲氧基苯甲酰胺 | 54090-25-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: N-(4-羟基苯基)-2-甲氧基苯甲酰胺
• 英文名称: N-(4-hydroxyphenyl)-2-methoxybenzamide
• CAS: 54090-25-4
• 化学式: C₁₄H₁₃NO₃
• 分子量: 243.262
• InChiKey: LXNXWBLKTWRVII-UHFFFAOYSA-N

物化性质

• 沸点：
  355.5±27.0 °C(Predicted)
• 密度：
  1.275±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  18
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  58.6
• 氢给体数：
  2
• 氢受体数：
  3

安全信息

• 海关编码：
  2924299090

反应信息

• 作为反应物：
  描述：

  N-(4-羟基苯基)-2-甲氧基苯甲酰胺 、 1-[4-乙酰氨基苯氧基]-3-氯丙烷 在 potassium carbonate 、 potassium iodide 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 0.5h， 以61%的产率得到N-(4-(3-(4-acetamidophenoxy)propoxy)phenyl)-2-methoxybenzamide
  参考文献：
  名称：

  用于治疗阿尔茨海默病的乙酰胆碱酯酶和β-分泌酶双重抑制剂的基于药物重新定位的设计、合成和生物学评价

  摘要：

  多功能药物的使用可以作为治疗阿尔茨海默病 (AD) 等神经退行性疾病的关键策略。为了寻找用于治疗 AD 的多靶点定向配体，已经使用计算机工具进行了药物重新定位研究。为此目的，对包含 4199 种 FDA 批准药物的库（药物中央数据库）进行了虚拟筛选，地诺巴胺、胍乙啶和丙脒被确定为靶向乙酰胆碱酯酶 (AChE) 和 β-分泌酶 (BACE-1) 的目标。此外，还进行了 MM/GBSA 和 MD 模拟分析，表明丙脒是一种抗菌和抗真菌药物，可能成为设计用于 AD 治疗的多靶点定向配体的关键药效​​团。最后，合成了一系列结构修饰的丙脒衍生物，通过在两端用取代的苯甲酰胺和乙酰胺部分取代末端脒来合成、表征和测试它们的抗 AD 作用。结构修饰的丙脒系列化合物27在亚微摩尔浓度范围内显示出显着的体外hAChE 和 hBACE-1 抑制作用（hAChE：IC 50  = 0.832 ± 0.05 µM 和 hBACE-1：IC

  DOI：

  10.1016/j.molstruc.2022.132979
• 作为产物：
  描述：

  对氨基苯酚 、 甲氧基苯甲酰氯 在 三乙胺 作用下， 以 1,4-二氧六环 为溶剂， 反应 3.0h， 生成 N-(4-羟基苯基)-2-甲氧基苯甲酰胺
  参考文献：
  名称：

  Synthesis and antiarrhythmic and parasympatholytic properties of substituted phenols. 2. Amides

  摘要：

  Thirty amides patterned after the antiarrhythmic drug changrolin were synthesized and their antiarrhythmic and parasympatholytic activities were assessed. There was no correlation between antiarrhythmic and parasympatholytic activities. Several of the amides were found to be potent antiarrhythmic agents that possessed low parasympatholytic activity. All of the compounds appear to act by a class I mechanism.

  DOI：

  10.1021/jm00376a022

文献信息

• Modulators of peroxisome proliferator activated receptors
  申请人：Brooks Alisa Dawn

  公开号：US20050020684A1

  公开（公告）日：2005-01-27

  Disclosed is a compound represented by Structural Formula (I): Ar is a substituted or unsubstituted aromatic group. Q is a covalent bond, —CH 2 — or —CH 2 CH 2 —; W is a substituted or unsubstituted alkylene or a substituted or unsubstituted heteroalkylene linking group from two to ten atoms in length, preferably from two to seven atoms in length. Phenyl Ring A is optionally substituted with up to four substituents in addition to R 1 and W, R 2 is (CH 2 ) n —CH(OR 2 )—(CH 2 ) n E, —(CH)═C(OR 2 )—(CH 2 ) n E, —(CH 2 ) n —CH(Y)—(CH 2 ) m E or (CH)═C(Y)(CH 2 ) m E; wherein E is COOR 3 , C 1 -C 3 alkylnitrile, carboxamide, sulfonamide, acylsulfonamide or tetrazole and wherein sulfonamide, acylsulfonamide and tetrazole are optionally substituted with one or more substituents independently selected from: C 1 -C 6 alkyl, haloalkyl and aryl-C o - 4 -alkyl; R 2 is H, an aliphatic group, a substituted aliphatic group, haloalkyl, an aromatic group, a substituted aromatic group, —COR 4 , —COOR 4 , —CONR 5 R 6 , —C(S)R 4 , —C(S)OR 4 or C(S)NR 5 R 6 , R 3 is H, an aliphatic group, a substituted aliphatic group, an aromatic group or a substituted aromatic group. Y is O—, CH 2 —, CH 2 CH 2 — or CH═CH— and is bonded to a carbon atom in Phenyl Ring A that is ortho to R 1 . R 4 -R 6 are independently H, an aliphatic group, a substituted aliphatic group, an aromatic group or a substituted aromatic group. n and m are independently 0, 1 or 2.

  本发明公开了一种由结构式（I）表示的化合物：其中Ar是取代或未取代的芳香基团。Q是共价键，-CH2-或-CH2CH2-; W是取代或未取代的烷基或取代或未取代的异烷基连接基，长度为两到十个原子，优选长度为两到七个原子。苯环A可选地与R1和W以外的最多四个取代基取代，R2是（CH2）n-CH（OR2）-（CH2）nE，-（CH）=C（OR2）-（CH2）nE，-（CH2）n-CH（Y）-（CH2）mE或（CH）=C（Y）（CH2）mE;其中E是COOR3，C1-C3烷基腈，羧酰胺，磺酰胺，酰基磺酰胺或四唑，磺酰胺，酰基磺酰胺和四唑可选地与一个或多个取代基取代，独立地选自：C1-C6烷基，卤代烷基和芳基-Co-4-烷基; R2是H，脂肪基，取代脂肪基，卤代烷基，芳基，取代芳基，-COR4，-COOR4，-CONR5R6，-C（S）R4，-C（S）OR4或C（S）NR5R6，R3是H，脂肪基，取代脂肪基，芳基或取代芳基。Y是O-，CH2-，CH2CH2-或CH═CH-，并与Phenyl环A中与R1相邻的碳原子键合。R4-R6独立地是H，脂肪基，取代脂肪基，芳基或取代芳基。n和m独立地为0、1或2。
• MODULATORS OF PEROXISOME PROLIFERATOR ACTIVATED RECEPTORS
  申请人：ELI LILLY AND COMPANY

  公开号：EP1392637A2

  公开（公告）日：2004-03-03
• US7192982B2
  申请人：——

  公开号：US7192982B2

  公开（公告）日：2007-03-20
• [EN] MODULATORS OF PEROXISOME PROLIFERATOR ACTIVATED RECEPTORS<br/>[FR] MODULATEURS DE RECEPTEURS ACTIVES PAR LE PROLIFERATEUR DE PEROXYSOME
  申请人：LILLY CO ELI

  公开号：WO2002100813A2

  公开（公告）日：2002-12-19

  Disclosed is a compound represented by Structural Formula (I): Ar is a substituted or unsubstituted aromatic group. Q is a covalent bond, -CH2-or-CH2CH2-; W is a substituted or unsubstituted alkylene or a substituted or unsubstituted heteroalkylene linking group from two to ten atoms in length, preferably from two to seven atoms in length. Phenyl Ring A is optionally substituted with up to four substituents in addition to R1 and W. R1 is (CH2)n-CH(OR2)-(CH2)mE, -(CH)=C(OR2)-(CH2)mE, -(CH2)n-CH(Y)-(CH2)mE or (CH)=C(Y)-(CH2)mE; wherein E is COOR3, C1-C3 alkylnitrile, carboxamide, sulfonamide, acylsulfonamide or tetrazole and wherein sulfonamide, acylsulfonamide and tetrazole are optionally substituted with one or more substituents independently selected from: C1-C6 alkyl, haloalkyl and aryl-C0-4-alkyl; R2 is H, an aliphatic group, a substituted aliphatic group, haloalkyl, an aromatic group, a substituted aromatic group, -COR4, -COOR4, -CONR5R6, -C(S)R4, -C(S)OR4 or C(S)NR5R6. R3 is H, an aliphatic group, a substituted aliphatic group, an aromatic group or a substituted aromatic group. Y is O-, CH2-, -CH2CH2- or CH=CH- and is bonded to a carbon atom in Phenyl Ring A that is ortho to R1. R4-R6 are independently H, an aliphatic group, a substituted aliphatic group, an aromatic group or a substituted aromatic group. n and m are independently 0, 1 or 2.
• Synthesis and antiarrhythmic and parasympatholytic properties of substituted phenols. 2. Amides
  作者：David M. Stout、W. L. Matier、Cynthia Barcelon-Yang、Robert D. Reynolds、Barry S. Brown

  DOI：10.1021/jm00376a022

  日期：1984.10

  Thirty amides patterned after the antiarrhythmic drug changrolin were synthesized and their antiarrhythmic and parasympatholytic activities were assessed. There was no correlation between antiarrhythmic and parasympatholytic activities. Several of the amides were found to be potent antiarrhythmic agents that possessed low parasympatholytic activity. All of the compounds appear to act by a class I mechanism.